

## LEUKOCARE Continues to Expand and Invests in Research and Development

The biotech company LEUKOCARE AG is experiencing strong growth and expanding both its premises and its workforce. The company is also planning to invest up to Euro 1 million in the expansion of its research and development activities.

---

### **Munich, September 14, 2017**

The biotech company LEUKOCARE AG, founded in 2003, is continuing to grow. Thanks to strong business development and numerous new orders for development projects based on its formulation platform, the company has moved into additional laboratory and office space in the IZB (Innovations- und Gründerzentrum Biotechnologie) building in Martinsried, near Munich. This expansion doubles the total amount of space occupied by the company, which has been based in the IZB building since 2010.

The company's growth is accompanied by a significant expansion of its research and development activities. As a result, the company is planning to invest up to Euro 1 million this year and next. The money will primarily be spent on new analytical equipment and methods.

Alongside this, the company's workforce has also grown significantly. After having 16 employees at the start of 2016, the company now has 25. By the end of the year, this number is set to rise further to as many as 30.

Michael Scholl, CEO of LEUKOCARE, describes the company's development as follows: "We have expanded our resources to take account of our current growth. In the current financial year alone, the number of employees and projects will increase by well over 50 percent. In view of our strong order books, we anticipate that this robust growth will continue, and we will be continuing to invest in the site accordingly."

In February of this year, LEUKOCARE announced a strategic alliance with Rentschler Biotechnologie GmbH from Laupheim. Under the terms of the alliance, the companies have agreed that LEUKOCARE will act as Rentschler's exclusive technology partner for formulation development on biopharmaceutical development projects. In return, Rentschler has taken a ten percent share in LEUKOCARE. LEUKOCARE is also continuing to use

its proprietary SPS<sup>®</sup> formulation technologies for the stabilization of biological molecules in projects with pharmaceutical and medical device companies.

### **About LEUKOCARE AG**

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS<sup>®</sup>) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS<sup>®</sup> technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS<sup>®</sup> technologies also protect proteins in biologically functionalized combination devices.

[www.leukocare.com](http://www.leukocare.com)

Contact:

Michael Scholl

[michael.scholl@leukocare.com](mailto:michael.scholl@leukocare.com)

+49(0)8978016650